NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026
Podium presentation by Co-Founder and Chief Research Officer Laura van ’t Veer introduces an AI-driven approach to MammaPrint Two additional poster presentations from the FLEX Study IRVINE, Calif., and AMSTERDAM, NETHERLANDS, September 25, 2026. Read More
Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients
Agendia’s landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care IRVINE, Calif, and AMSTERDAM — Sept 24, 2026 — Agendia®, Inc., a leader in precision Read More
Agendia Announces Definitive, Mandatory Swiss Health Insurance Reimbursement for MammaPrint
Effective 1 July 2026, Switzerland’s FOPH completes its review of multigene expression testing, formally deciding to continue reimbursement indefinitely IRVINE, Calif, and AMSTERDAM — July 14, 2026 — Agendia®, Inc., a leader in precision Read More
Newsroom
News, Stories & Breast Cancer Blog
How One Test Changed The Course of My Breast Cancer Journey
Not every woman with early-stage breast cancer needs chemotherapy. Genomic tests like MammaPrint are helping doctors determine who does. When I was diagnosed with Stage IIA breast cancer in late 2017, I thought Read More
What Does a MammaPrint High Risk Result Mean?
MammaPrint evaluates the expression of 70 genes associated with breast cancer behavior and recurrence risk. MammaPrint High Risk tumors are more likely to benefit from chemotherapy than Low Risk tumors.
Cancer Diagnostics Are Expanding As New Approaches Provide a Broader View of Tumor Biology and Disease Progression
For years, a cancer diagnosis often came down to one test, one gene, one mutation. Today, clinical laboratories are adopting broader approaches—including whole-genome sequencing, functional RNA profiling, liquid biopsy, and multi-omic testing—that provide more comprehensive Read More
Core Needle Biopsy and Genomic Testing in Breast Cancer
Hearing the words “you need a biopsy” or “we found something suspicious” during a clinical breast exam, mammogram, or MRI can stop everything in its tracks. Feeling worried or uncertain in that moment is Read More
ASCO 2026: Genomics Reveal HRD–Treatment Response Link
Gene expression profiling links HRD in patients with high risk breast cancer with anthracycline outcomes Steven Isakoff, Breast Medical Oncologist at Mass General Brigham Cancer Institute, shares findings from a 70-gene signature breast Read More
Health Rounds: Genomic Testing Improves Treatment, Survival for Black Breast Cancer Patients
Advanced genomic testing could help erase significant disparities in breast cancer survival rates between white and Black patients, new research has found. Currently, Black women in the U.S. have a 40% higher breast cancer mortality Read More
Genomic Testing Finds a Higher Prevalence of High-Risk Breast Cancer in Black Women
These findings highlight the critical need for tumor genomic testing for all patients to identify those with high-risk tumors, which occur more frequently in Black women, and which require more aggressive treatment to prevent Read More
